Skip to content

Study · In vitro (cells) · 2024

4 results

Anti-Cancer Peptide PNC-27 Kills Cancer Cells by Unique Interactions with Plasma Membrane-Bound hdm-2 and with Mitochondrial Membranes Causing Mitochondrial Disruption.

Krzesaj P, Adler V, Feinman RD, Miller A, Silberstein M, Yazdi E, Pincus MR

Annals of clinical and laboratory science1 Mar 2024Cited by 1 (Europe PMC)

PMID38802154 (opens in a new tab)PepBankPUB-38802154
Publisher pageAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Mechanism

    In pancreatic carcinoma cells, mitochondria failed to retain mitotracker after PNC‑27 treatment.

    In plain wordsIn cells, mitochondria failed to retain the mitochondrial dye after PNC‑27 treatment.

    Peptide
    PNC-27
    Outcome
    DecreaseMitochondrial dye retention
    Study

    humann: not reported in source

    MIA-PaCa-2 pancreatic carcinoma cells
    Outcome group
    Mitochondrial function · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The mitochondria of PNC-27-treated cancer cells fail to retain mitotracker dye while their lysosomes retain lysotracker dye.
    2 context sentences
    Summary · context
    For aim 1, we incubated MIA-PaCa-2 human pancreatic carcinoma cells with PNC-27 in the presence of a monoclonal antibody against the amino terminal p53 binding site of HDM-2 to determine if it, but not negative control immune serum, blocks PNC-27-induced tumor cell necrosis.
    Summary · context
    For the second aim, we incubated these cells with PNC-27 in the presence of two specific dyes that highlight normal organelle function: mitotracker for mitochondria and lysotracker for lysosomes.
  2. 02LabIn vitro (cells)Mechanism

    In pancreatic carcinoma cells, lysosomes retained lysotracker after PNC‑27 treatment.

    In plain wordsIn cells, lysosomes retained the lysosomal dye after PNC‑27 treatment.

    Peptide
    PNC-27
    Outcome
    Not applicableLysosomal dye retention
    Study

    humann: not reported in source

    MIA-PaCa-2 pancreatic carcinoma cells
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The mitochondria of PNC-27-treated cancer cells fail to retain mitotracker dye while their lysosomes retain lysotracker dye.
    2 context sentences
    Summary · context
    For aim 1, we incubated MIA-PaCa-2 human pancreatic carcinoma cells with PNC-27 in the presence of a monoclonal antibody against the amino terminal p53 binding site of HDM-2 to determine if it, but not negative control immune serum, blocks PNC-27-induced tumor cell necrosis.
    Summary · context
    For the second aim, we incubated these cells with PNC-27 in the presence of two specific dyes that highlight normal organelle function: mitotracker for mitochondria and lysotracker for lysosomes.
  3. 03LabIn vitro (cells)Mechanism

    In pancreatic carcinoma cells, immuno-electron microscopy localized PNC‑27 antibody gold labels to mitochondrial membranes.

    In plain wordsIn cells, microscopy detected PNC‑27 labels on mitochondrial membranes.

    Peptide
    PNC-27
    Outcome
    Not applicableMitochondrial membrane localization
    Study

    humann: not reported in source

    MIA-PaCa-2 pancreatic carcinoma cells
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    IEM of the mitochondria cancer cells reveals gold particles present on the mitochondrial membranes.
    3 context sentences
    Summary · context
    We also performed immuno-electron microscopy (IEM) with gold-labeled anti-PNC-27 antibody on the mitochondria of these cells treated with PNC-27.
    Summary · context
    For aim 1, we incubated MIA-PaCa-2 human pancreatic carcinoma cells with PNC-27 in the presence of a monoclonal antibody against the amino terminal p53 binding site of HDM-2 to determine if it, but not negative control immune serum, blocks PNC-27-induced tumor cell necrosis.
    Summary · context
    For the second aim, we incubated these cells with PNC-27 in the presence of two specific dyes that highlight normal organelle function: mitotracker for mitochondria and lysotracker for lysosomes.

Studies that did not test the peptide alone1

In this study, PNC-27 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking PNC-27.

  1. 04LabNot a test of PNC-27 aloneIn vitro (cells)Mechanism

    In pancreatic carcinoma cells, antibody against the HDM-2 p53 binding site blocked PNC‑27-induced necrosis, unlike control immune serum.

    In plain wordsIn cells, the antibody blocked PNC‑27-induced cell death, unlike control immune serum.

    Peptide
    PNC-27
    Outcome
    DecreaseAntibody blockade of necrosis
    Study

    humann: not reported in source

    MIA-PaCa-2 pancreatic carcinoma cells
    Comparator
    negative control immune serum
    Outcome group
    Receptor activity and mechanism · Cancer

    Source sentences

    Summary
    Monoclonal antibody to the p53 binding site of HDM-2 blocks PNC-27-induced cancer cell necrosis, whereas negative control immune serum does not.
    2 context sentences
    Summary · context
    For aim 1, we incubated MIA-PaCa-2 human pancreatic carcinoma cells with PNC-27 in the presence of a monoclonal antibody against the amino terminal p53 binding site of HDM-2 to determine if it, but not negative control immune serum, blocks PNC-27-induced tumor cell necrosis.
    Summary · context
    For the second aim, we incubated these cells with PNC-27 in the presence of two specific dyes that highlight normal organelle function: mitotracker for mitochondria and lysotracker for lysosomes.

    In this study, PNC-27 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking PNC-27.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.